by Clinical Neuropsychologist Online | Thursday, August 20, 2026 | Dementia
Abstract INTRODUCTION Plasma p-tau217 and p-tau217/Aβ42 reliably identify non-Hispanic White individuals with symptomatic and pre-clinical AD. However, performance across ethnoracially diverse groups remains unknown. METHODS Cognitively normal Black, Hispanic, and...
by Clinical Neuropsychologist Online | Thursday, August 20, 2026 | Dementia
Abstract INTRODUCTION The plasma proteomic signatures underlying cerebrovascular disease (CeVD) remains poorly understood. METHODS A total of N = 2534 participants across two independent longitudinal Southeast-Asian cohorts were included. We profiled 1441 baseline...
by Clinical Neuropsychologist Online | Thursday, August 20, 2026 | Dementia
Abstract INTRODUCTION Quantification approaches based on group-level regions of interest (ROIs) are widely used for evaluating tau positron emission tomography (PET) and clinical progression in Alzheimer’s disease (AD), but we hypothesize that personalized...
by Clinical Neuropsychologist Online | Thursday, August 20, 2026 | Dementia
Abstract INTRODUCTION Late-life depression is associated with cognitive impairment, but the underlying neural basis remains to be elucidated. We investigated the role of Alzheimer’s disease (AD)–related plasma biomarkers in the depression–cognition association....
by Clinical Neuropsychologist Online | Thursday, August 20, 2026 | Dementia
Abstract Increasing evidence suggests that myelin dysfunction and oligodendrocyte pathology are active contributors to neurodegeneration. In Alzheimer’s disease (AD), the link between tau aggregation and myelin integrity remains unclear, despite the preferential...
